The shares of one of the Pharma stock specializes in the manufacturing and marketing of a wide range of pharmaceutical products jumps 10 percent, upon following their Q3 Results with 707 percent rise in profit YoY
Price action
With a market capitalization of Rs. 1,515.44 crores on Thursday, the shares of Jagsonpal Pharmaceuticals Limited is up by 10.4 percent making a high of Rs. 251.95 per share compared to its previous closing price of Rs. 228.25 per share.
What Happened
Jagsonpal Pharmaceuticals Limited specializes in the manufacturing and marketing of a wide range of pharmaceutical products have announced their Q3FY25 results
Its Total Income grew by 53.41 percent YoY from Rs. 49.77 Crores in Q3FY24 to Rs. 76.35 Crores in Q3FY25 and it grew by 0.013 percent QoQ from Rs. 76.34 Crores in Q2FY25 to Rs. 76.35 Crores in Q3FY25.
Its Net Profit rose 707.8 percent YoY from Rs. 3.96 Crores in Q3FY24 to Rs. 31.99 Crores in Q3FY25 and it rose by 179 percent QoQ from Rs.11.46 Crores in Q2FY25 to Rs. 31.99 Crores in Q3FY25.
About the company
Jagsonpal Pharmaceuticals Limited is an Indian pharmaceutical company, it focuses on therapeutic areas such as cardiology, orthopedics, gastroenterology, and dermatology, providing solutions to improve healthcare. It is known for its strong presence in the Indian market and exports to several international markets.
Operational Highlights Q3FY25
Jagsonpal Pharmaceuticals Limited reported strong performance in Q3FY25, achieving Rs. 740 million in quarterly sales, marking 57 percent growth compared to Q3FY24. The company successfully integrated its acquired business, with Q3FY25 being the second full quarter of performance in line with expectations.
The company demonstrated steady 5 percent YoY growth, driven by healthy market demand, according to IQVIA. Additionally, 8 out of 10 brands showed growth, reflecting the strength of its portfolio.
Outlook – FY25 and Beyond
Jagsonpal Pharmaceuticals Limited has a positive outlook, with expectations of achieving around 22 percent operating margins (pre-ESOP) and a revenue growth target of 30 percent plus in FY25. The company aims for 12–14 percent growth in revenue and anticipates an improvement of 100-150 basis points in operating margins beyond after 2025.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
